DRREDDY vs SANOFI: Stock Comparison

Dr Reddys Laboratories Ltd vs Sanofi India Limited

Live data: 22 July 2026, 3:03 PM IST • Source: NSE and company filings

Dr Reddys Laboratories Ltd is the larger company by market capitalisation. Dr Reddys Laboratories Ltd shows faster revenue growth, while Sanofi India Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Dr Reddys Laboratories Ltd and Sanofi India Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, DRREDDY is more favourable on 1 of 13 scored metrics and SANOFI on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DRREDDY is the larger company
₹98,815 Cr vs ₹7,850 Cr
P/E Ratio
SANOFI has a lower P/E
0x vs 24x
P/B Ratio
SANOFI has a lower P/B
0x vs 2.66x
EPS
SANOFI has higher earnings per share
₹134.59 vs ₹51.37
Dividend Yield
SANOFI has a higher dividend yield
7.15% vs 0.65%
Revenue Growth (TTM YoY)
DRREDDY has faster revenue growth
-11.6% vs -11.9%
EPS Growth (TTM YoY)
SANOFI has faster EPS growth
-14.1% vs -86.2%
Qtr Sales Growth
SANOFI has stronger quarterly sales growth
9.74% vs -11.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDRREDDYSANOFI
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDRREDDYSANOFI
Live Price₹1,183.9₹3,415
Day Change-1.83%0.94%
Volume21.26 L13,127
52-Week High₹1,414.9₹5,955
52-Week Low₹1,148.4₹3,054
Distance from 52W High-16.33%-42.65%

Valuation

MetricDRREDDYSANOFI
Market Cap₹98,815 Cr₹7,850 Cr
P/E Ratio24x0x
P/B Ratio2.66x0x
EPS₹51.37₹134.59
Book Value₹452.82₹325.31
Dividend Yield0.65%7.15%

Growth

MetricDRREDDYSANOFI
Revenue Growth (TTM YoY)-11.6%-11.9%
EPS Growth (TTM YoY)-86.2%-14.1%
Qtr Sales Growth-11.5%9.74%
Qtr Profit Growth-86.1%22.4%

Profitability & Leverage

MetricDRREDDYSANOFI
ROE11.2%47.1%
ROCE13%49.2%
Net Margin12.76%19.26%
Operating Margin19.2%24.4%
Debt to Equity0.2x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricDRREDDYSANOFI
Promoter Holding26.63% 0.01 pp0%
FII Holding33.08% 0.12 pp5.64% 0.09 pp
DII Holding30.72% 0.28 pp21.13% 0.18 pp
Public Holding9.33% 0.14 pp12.83% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Dr Reddys Laboratories Ltd and Sanofi India Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.